Alternative pathway to malaria infection identified

Jun 17, 2010

Discovery of a key red cell molecule used by the malaria parasite gives renewed hope for an effective vaccine in the future, according to an international team of researchers.

Plasmodium falciparum, a blood parasite that causes by invading and multiplying in the red blood cells, kills 1 to 2 million people annually.

"How the parasite invades is not completely understood," said Jose A. Stoute, M.D., senior investigator and team leader, Department of Medicine, Division of and Epidemiology, Penn State College of Medicine. "For many years it has been known that proteins called glycophorins are used by the parasite to gain entry into the red cell."

Because infection can take place without glycophorins, researchers suspected that another is also involved. The identity of this protein remained a mystery for 20 years and it was named the "X" receptor. A team of researchers now reports in today's (June 17) issue of PLoS Pathogens, the identity of this protein as the complement receptor 1 (CR1), also known to help protect red cells from attack by the immune system. CR1 has been suspected of having other roles in the development of malaria complications. The team was able to demonstrate that this protein is important in the invasion of red cells by using several laboratory strains of malaria as well as strains obtained from Kenya.

"Our findings suggest that for many malaria strains, CR1 is an alternative receptor to glycophorins on intact red cells," Stoute said.

According to the researchers, the reasons malaria may use the CR1 protein instead of glycophorins are if the parasite encounters a variant that lacks the glycophorin receptor; if the immune system mounts a response against parasite proteins involved in the dominant pathway due to a previous infection; or if the host were to be vaccinated with a vaccine that blocks the glycophorin pathway.

"This work has important implications for the future development of a vaccine against malaria," Stoute said. "Therefore, it is imperative that all the major invasion pathways be represented in a future malaria blood stage vaccine."

Vaccines that target parasite proteins involved in the dominant glycophorin pathway, but do not block the CR1 pathway, may cause proliferation of parasites that rely on the CR1 pathway for infection.

"The demonstration that CR1 is a receptor of P. falciparum will facilitate the identification of additional parasite proteins that allow it to bind to the blood cell, and the future development of a vaccine that effectively blocks red cell invasion," said Carmenza Spadafora, lead author and scientist at the Institute for Advanced Science and High Technology Studies, Republic of Panama.

Explore further: 3-D human skin maps aid study of relationships between molecules, microbes and environment

Related Stories

How adhesive protein causes malaria

Sep 25, 2007

Researchers at the Swedish medical university Karolinska Institutet (KI) and the Swedish Institute for Infectious Disease Control (SMI) have identified the biochemical mechanism behind the adhesive protein that give rise ...

Blood-thinning copycat enters malaria fight

Jun 01, 2010

New treatments for malaria are possible after Walter and Eliza Hall Institute scientists found that molecules similar to the blood-thinning drug heparin can stop malaria from infecting red blood cells.

How the malaria parasite hijacks human red blood cells

Jul 08, 2008

A new study—done on a scale an order of magnitude greater than anything previously attempted in the field of malaria—has uncovered an arsenal of proteins produced by the malaria parasite that allows it to hijack and remodel ...

Recommended for you

'Google Maps' for the body: A biomedical revolution

11 hours ago

A world-first UNSW collaboration that uses previously top-secret technology to zoom through the human body down to the level of a single cell could be a game-changer for medicine, an international research ...

New compounds could offer therapy for multitude of diseases

12 hours ago

An international team of more than 18 research groups has demonstrated that the compounds they developed can safely prevent harmful protein aggregation in preliminary tests using animals. The findings raise hope that a new ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.